Related Experiment Video
Updated: Oct 30, 2025
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies
Ibrahim M El-Deeb1, Valeria Pittala2, Diab Eltayeb3
1Department of Medical Sciences, Royal College of Surgeons in Ireland, Medical University of Bahrain, Busaiteen 228, Bahrain.
Abstract:
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of tumors that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. The mainstay of treatment remains chemotherapy, but the therapeutic outcome remains inadequate. This paper investigates the potential of a duocarmycin derivative, tafuramycin A (TFA), as a new and more effective chemotherapy agent in TNBC treatment. To this extent, we optimized the chemical synthesis of TFA, and we encapsulated TFA in a micellar system to reduce side effects and increase tumor accumulation. In vitro and in vivo studies suggest that both TFA and SMA-TFA possess high anticancer effects in TNBC models. Finally, the encapsulation of TFA offered a preferential avenue to tumor accumulation by increasing its concentration at the tumor tissues by around four times in comparison with the free drug. Overall, the results provide a new potential strategy useful for TNBC treatment.
Insights
Tafuramycin A (TFA) shows promise as a novel chemotherapy for triple-negative breast cancer (TNBC). Encapsulating TFA in micelles enhances its delivery and efficacy, offering a potential new treatment strategy for TNBC patients.
Area of Science:
- Oncology
- Pharmacology
- Drug Delivery
Background:
- Triple-negative breast cancer (TNBC) lacks targeted therapies, with chemotherapy offering inadequate outcomes.
- Existing treatments for TNBC have limitations in efficacy and side effect profiles.
Purpose of the Study:
- To evaluate tafuramycin A (TFA), a duocarmycin derivative, as a novel chemotherapy agent for TNBC.
- To develop a micellar system for TFA encapsulation to improve tumor targeting and reduce toxicity.
Main Methods:
- Optimized chemical synthesis of tafuramycin A (TFA).
- Encapsulated TFA in a micellar system (SMA-TFA).
- Assessed anticancer effects of TFA and SMA-TFA in vitro and in vivo TNBC models.
Main Results:
- Both TFA and SMA-TFA demonstrated significant anticancer activity in TNBC models.
- Micellar encapsulation of TFA increased its concentration in tumor tissues approximately fourfold compared to the free drug.
- The SMA-TFA formulation showed reduced side effects and enhanced tumor accumulation.
Conclusions:
- Tafuramycin A is a potent agent against TNBC.
- Micellar encapsulation of TFA represents a promising strategy to improve its therapeutic index for TNBC treatment.
- This approach offers a potential new avenue for more effective TNBC therapy.
